Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malonic Acid SCHEMBL27560828 | 1.00 | STAT3 (0.36) | STAT3STAT1LDHASRREGLN1 | |
| Propionic Acid SCHEMBL2502176 | 0.87 | FFAR3 (0.36) | STAT3STAT1MEN1KMT2A | |
| Glycine SCHEMBL14801761 | 0.87 | GLRA1 (0.36) | STAT3STAT1ALDH1A1MAPT | |
| Propionic Acid SCHEMBL27439210 | 0.87 | FFAR3 (0.36) | STAT3STAT1MEN1KMT2A | |
| Hydrogen Peroxide SCHEMBL28310892 | 0.86 | STAT3 (0.43) | STAT3STAT1 | |
| Propionic Acid SCHEMBL27367545 | 0.86 | STAT3 (0.35) | STAT3STAT1 | |
| SCHEMBL28643450 | 0.85 | STAT3 (0.38) | STAT3STAT1 | |
| Carbamic Acid SCHEMBL30568294 | 0.85 | STAT3 (0.38) | STAT3STAT1 | |
| SCHEMBL28505872 | 0.84 | MAPT (0.35) | STAT3STAT1KDM4EMEN1ALDH1A1 | |
| Acetic Acid SCHEMBL29181911 | 0.83 | STAT3 (0.37) | STAT3STAT1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080283122-A1 | Beta-Substituted Porphyrins | CAMPBELL WAYNE MASON | 2008-11-20 | — | — | US | disclosed |
| CN-1303090-C | Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases | ZENTARIS AG (DE) | 2007-03-07 | — | — | CN | disclosed |
| US-7087214-B2 | Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases | ZENTARIS GMBH (DE) | 2006-08-08 | — | — | US | disclosed |
| WO-2006038823-A1 | BETA-SUBSTITUTED PORPHYRINS | MASSEY UNIVERSITY (NZ) | 2006-04-13 | — | — | WO | disclosed |
| CN-1639178-A | Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases | ZENTARIS AG (DE) | 2005-07-13 | — | — | CN | disclosed |
| EP-1470139-A2 | NOVEL, WATER−SOLUBLE PORPHYRIN PLATINUM COMPOUNDS WITH HIGH TUMOR SELECTIVITY AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOR DISEASES | Zentaris GmbH (DE) | 2004-10-27 | — | — | EP | disclosed |
| US-20040023942-A1 | Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases | ZENTARIS GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| WO-2003064424-A2 | WATER-SOLUBLE PORPHYRIN PLATINUM COMPOUNDS WITH HIGH TUMOR SELECTIVITY AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOR DISEASES | ZENTARIS GMBH (DE) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023942-A1 | Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases | PPOX, VHL, SLC40A1 | STAT3 1854/4885STAT1 2558/4885LDHA 537/4885 |
| US-20080283122-A1 | Beta-Substituted Porphyrins | PPOX, HMBS, CRY1 | STAT3 3336/4885STAT1 4389/4885LDHA 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.